Sino Biopharmaceutical Statistics
Sino Biopharmaceutical (SMZ1) Stock Statistics & Valuation Metrics
Total Valuation
Sino Biopharmaceutical has a market cap or net worth of CHF 10.41B. The enterprise value is CHF 83.38B.
- Market Cap
- CHF 10.41B
- Enterprise Value
- CHF 83.38B
Share Statistics
Sino Biopharmaceutical has 18,682,953,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 18,682,953,000
- Owned by Insiders
- 15.79%
- Owned by Institutions
- 9.03%
Financial Efficiency
Sino Biopharmaceutical’s return on equity (ROE) is 0.08 and return on invested capital (ROIC) is 8.98%.
- Return on Equity (ROE)
- 0.08
- Return on Assets (ROA)
- 0.03
- Return on Invested Capital (ROIC)
- 8.98%
- Return on Capital Employed (ROCE)
- 0.14
- Revenue Per Employee
- 1.39M
- Profits Per Employee
- 102.61K
- Employee Count
- 22,838
- Asset Turnover
- 0.42
- Inventory Turnover
- 2.53
Valuation Ratios
The current PE Ratio of Sino Biopharmaceutical is 34.61. Sino Biopharmaceutical’s PEG ratio is -0.85.
- PE Ratio
- 34.61
- PS Ratio
- 2.43
- PB Ratio
- 2.55
- Price to FCF
- 15.86
- Price to Operating Cash Flow
- 13.55
- PEG Ratio
- -0.85
Income Statement
In the last 12 months, Sino Biopharmaceutical had revenue of 31.83B and earned 2.34B in profits. Earnings per share was 0.13.
- Revenue
- 31.83B
- Gross Profit
- 26.13B
- Operating Income
- 6.95B
- Pretax Income
- 6.94B
- Net Income
- 2.34B
- EBITDA
- 7.50B
- Earnings Per Share (EPS)
- 0.13
Cash Flow
In the last 12 months, operating cash flow was 6.13B and capital expenditures -967.92M, giving a free cash flow of 5.16B billion.
- Operating Cash Flow
- 6.13B
- Free Cash Flow
- 5.16B
- Free Cash Flow per Share
- 0.29
Dividends & Yields
Sino Biopharmaceutical pays an annual dividend of ―, resulting in a dividend yield of 1.89%
- Dividend Per Share
- ―
- Dividend Yield
- 1.89%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 6.31%
- Earnings Yield
- 2.88%
Stock Price Statistics
- Beta
- -0.67
- 52-Week Price Change
- 9.23%
- 50-Day Moving Average
- 0.56
- 200-Day Moving Average
- 0.54
- Relative Strength Index (RSI)
- 54.87
- Average Volume (3m)
- ―
Important Dates
Sino Biopharmaceutical upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 19, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Sino Biopharmaceutical as a current ratio of 1.37, with Debt / Equity ratio of 52.39%
- Current Ratio
- 1.37
- Quick Ratio
- 1.28
- Debt to Market Cap
- 0.16
- Net Debt to EBITDA
- 0.52
- Interest Coverage Ratio
- 25.65
Taxes
In the past 12 months, Sino Biopharmaceutical has paid 1.63B in taxes.
- Income Tax
- 1.63B
- Effective Tax Rate
- 0.23
Enterprise Valuation
Sino Biopharmaceutical EV to EBITDA ratio is 7.88, with an EV/FCF ratio of 16.29.
- EV to Sales
- 2.50
- EV to EBITDA
- 7.88
- EV to Free Cash Flow
- 16.29
- EV to Operating Cash Flow
- 13.72
Balance Sheet
Sino Biopharmaceutical has CHF 27.58B in cash and marketable securities with CHF 17.17B in debt, giving a net cash position of CHF 10.41B billion.
- Cash & Marketable Securities
- CHF 27.58B
- Total Debt
- CHF 17.17B
- Net Cash
- CHF 10.41B
- Net Cash Per Share
- CHF 0.56
- Tangible Book Value Per Share
- CHF 2.11
Margins
Gross margin is 82.43%, with operating margin of 29.76%, and net profit margin of 7.09%.
- Gross Margin
- 82.43%
- Operating Margin
- 29.76%
- Pretax Margin
- 24.67%
- Net Profit Margin
- 7.09%
- EBITDA Margin
- 31.68%
- EBIT Margin
- 28.17%
Analyst Forecast
The average price target for Sino Biopharmaceutical is CHF 0.97, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- CHF 0.97
- Price Target Upside
- 71.00% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 9
- Revenue Growth Forecast
- 4.45%
- EPS Growth Forecast
- -38.06%
Scores
- Smart Score
- 5
- AI Score
- ―

